xmas 2015, page-33

Hi Andante, Calimmune have a non-exclusive licence, so I wouldn't expect more than 5%. BLT had no money to progress the HIV program, so I am thankful that Calimmune have taken up the challenge. BLT couldn't convince the right people it was worth pursuing and live in a country that doesn't give a stuff about supporting biotech. There really is nothing we can do without a lab and without sufficient money to establish one.

Interest in BLT will pick up if there is good news from Calimmune or the HCV program. Look at the Uni of Penn leukemia study. They had four bigpharma negotiating with them when they released their outstanding results in just 2 out of 3 patients and eventually settled on Novartis. This is despite the assumption that BigPharma are disinterested in gene therapy and personalised medicine. They just need to see results, which to date haven't been great, unless you count Gradalis, who are keeping very quiet. According to Mary Crowley's latest newsletter, they are only 'considering' applying for Breakthough Therapy Designation.